Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

  1. Mateos, M.V.
  2. Weisel, K.
  3. Terpos, E.
  4. Delimpasi, S.
  5. Kastritis, E.
  6. Zamagni, E.
  7. Delforge, M.
  8. Ocio, E.
  9. Katodritou, E.
  10. Gay, F.
  11. Larocca, A.
  12. Leleu, X.
  13. Otero, P.R.
  14. Schjesvold, F.
  15. Cavo, M.
  16. Dimopoulos, M.A.
Aldizkaria:
Haematologica

ISSN: 1592-8721,  0390-6078

Argitalpen urtea: 2024

Alea: 109

Zenbakia: 7

Orrialdeak: 2337-2340

Mota: Gutuna

DOI: 10.3324/HAEMATOL.2023.284694 GOOGLE SCHOLAR lock_openSarbide irekia editor
Datuen iturria: Scopus